Entyvio 108 MG/0.68 ML pen 0.68ML
Ended Awarded
- Contract number
- SPE2DB26FWAQA
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,459
Award facts
- Contract value 100% obligated
- $2,458.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $2,458.82 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Entyvio 108 mg/0.68 ml pen (vedolizumab), a biologic medication used to treat inflammatory bowel diseases. The contract, effective October 28, 2025, with an ultimate completion date of November 19, 2025, represents a non-competitive, non-set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, holds a significant role in the federal medical supply chain, particularly serving military and veteran healthcare systems through the Defense Logistics Agency. As a prime contractor under the DLA Troop Support Medical umbrella contract, the company demonstrates substantial capability in fulfilling federal pharmaceutical procurement requirements across multiple therapeutic domains. The DLA is transitioning to Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen Drug Corp to continue supporting critical medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DB26FWAQA?
SPE2DB26FWAQA was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DB26FWAQA worth?
The government has obligated $2,459 on SPE2DB26FWAQA.
Is contract SPE2DB26FWAQA an order under another contract?
Yes. SPE2DB26FWAQA is a delivery order under SPE2DB25D3022, an indefinite delivery contract.
Was contract SPE2DB26FWAQA competed?
The extent of competition for SPE2DB26FWAQA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award